Bapineuzumab would seem to be on somewhat shakier ground as a consequence of this deal. Nothing I heard from PFE suggests that they are bullish about the program.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”